Weight change and antiepileptic drugs - Health issues and criteria for appropriate selection of an antiepileptic agent

被引:14
作者
Biton, Victor [1 ]
机构
[1] Arkansas Epilepsy Program, Little Rock, AR 72205 USA
关键词
epilepsy; AED; weight change; review;
D O I
10.1097/01.nrl.0000202599.21758.9a
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Antiepileptic drugs (AEDs) constitute a diverse class of agents with heterogeneous mechanisms of action and diverse side-effect profiles. Weight change, either gain or loss, is a common AED side effect, conferring multiple risks of additional morbidity. Review Summary: The risks inherent in weight change, such as diabetes, coronary heart disease (CHD), and polycystic ovary syndrome (PCOS), may be exacerbated by the interaction of polypharmacy and comorbidities. Patients with epilepsy are more likely to be receiving multiple medications and are also more likely than the general population to suffer from morbidities related to both weight gain and weight loss. For certain patients, use of an AED associated with weight change, particularly weight loss, may be salubrious, although long-term weight change in these patients may ultimately become undesirable. Appropriate selection of an AED to minimize the risk of morbidity arising from weight change should be guided by a knowledge of patients' weight status, their comorbidities, and use of other medications. The potential for added risk in certain subpopulations, such as pediatric, elderly, and female patients, requires additional caution in selecting an AED. Conclusions: Use of a weight-neutral AED is recommended to lessen the risk of dysfunction arising from weight change.
引用
收藏
页码:163 / 167
页数:5
相关论文
共 54 条
[1]
Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch [J].
Albani, F ;
Grassi, B ;
Ferrara, R ;
Turrini, R ;
Baruzzi, A .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2004, 13 (04) :254-263
[2]
Relationship between obesity and prostate cancer [J].
Amling, CL .
CURRENT OPINION IN UROLOGY, 2005, 15 (03) :167-171
[3]
Reproductive dysfunction in women with epilepsy:: recommendations for evaluation and management [J].
Bauer, J ;
Isojärvi, JIT ;
Herzog, AG ;
Reuber, M ;
Polson, D ;
Tauboll, E ;
Genton, P ;
van der Ven, H ;
Roesing, B ;
Luef, GJ ;
Galimberti, CA ;
van Parys, J ;
Flügel, D ;
Bergmann, A ;
Elger, CE .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02) :121-125
[4]
BECERRA JE, 1990, PEDIATRICS, V85, P1
[5]
Predictors of weight loss in adults with topiramate-treated epilepsy [J].
Ben-Menachem, E ;
Axelsen, M ;
Johanson, EH ;
Stagge, A ;
Smith, U .
OBESITY RESEARCH, 2003, 11 (04) :556-562
[6]
WEIGHT-LOSS IN PATIENTS TAKING FELBAMATE [J].
BERGEN, DC ;
RISTANOVIC, RK ;
WAICOSKY, K ;
KANNER, A ;
HOEPPNER, TJ .
CLINICAL NEUROPHARMACOLOGY, 1995, 18 (01) :23-27
[7]
WEIGHT-GAIN - A SIDE-EFFECT OF TRICYCLIC ANTIDEPRESSANTS [J].
BERKEN, GH ;
WEINSTEIN, DO ;
STERN, WC .
JOURNAL OF AFFECTIVE DISORDERS, 1984, 7 (02) :133-138
[8]
Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy [J].
Beydoun, A ;
Uthman, BM ;
Kugler, AR ;
Greiner, MJ ;
Knapp, LE ;
Garofalo, EA .
NEUROLOGY, 2005, 64 (03) :475-480
[9]
Effect of antiepileptic drugs on bodyweight - Overview and clinical implications of epilepsy [J].
Biton, V .
CNS DRUGS, 2003, 17 (11) :781-791
[10]
Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy [J].
Biton, V ;
Mirza, W ;
Montouris, G ;
Vuong, A ;
Hammer, AE ;
Barrett, PS .
NEUROLOGY, 2001, 56 (02) :172-177